Breaking News Instant updates and real-time market news.

FL

Foot Locker

$44.33

(0.00%)

, UA

Under Armour

$12.45

(0.00%)

09:16
12/15/17
12/15
09:16
12/15/17
09:16

On The Fly: Pre-market Movers

HIGHER: Foot Locker (FL), up 2.7% after being upgraded to Buy from Hold at Canaccord... Under Armour (UA, UAA), up 4.2% and 3.3%, respectively after being upgraded to Buy from Hold at Stifel... Polarityte (COOL), up 5.3% after announcing the application of SkinTE on first patients... Aclaris Therapeutics (ACRS), up 1.9% after receiving FDA approval for Eskata topical solution, 40%. LOWER: CSX (CSX), down 10.8% after announcing that CEO E. Hunter Harrison is on medical leave due to unexpected complications from a recent illness... Radius Health (RDUS), down 4.1% after announcing the Committee for Medicinal Products for Human Use will issue a third Day-180 List of Outstanding Issues. As part of its on-going risk-benefit assessment, the CHMP has informed the company that it intends to refer the marketing authorisation application, or MAA, to a scientific advisory group for additional advice.

FL

Foot Locker

$44.33

(0.00%)

UA

Under Armour

$12.45

(0.00%)

UAA

Under Armour

$13.82

(0.00%)

COOL

PolarityTE

$24.19

-1.95 (-7.46%)

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

CSX

CSX

$57.31

-0.38 (-0.66%)

RDUS

Radius Health

$28.66

-0.96 (-3.24%)

  • 24

    Dec

FL Foot Locker
$44.33

(0.00%)

12/04/17
12/04/17
DOWNGRADE

Hold
Foot Locker downgraded to Hold with 'rare loss' at Standpoint Research
As previously reported, Standpoint Research analyst Ronnie Moas downgraded Foot Locker to Hold from Buy, saying it "is very rare for me to close a position out at a loss" but following the 60% bounce from the stock's low he is doing that in this case. Moas now wonders if Foot Locker is a value trap given declining shopping mall numbers and foot traffic in the U.S.
12/15/17
ADAM
12/15/17
UPGRADE
ADAM
Buy
Foot Locker upgraded to Buy from Hold at Canaccord
12/04/17
STPT
12/04/17
DOWNGRADE
STPT
Hold
Foot Locker downgraded to Hold from Buy at Standpoint Research
12/15/17
12/15/17
UPGRADE
Target $64

Buy
Foot Locker upgraded to Buy on end of inventory clearance at Canaccord
As previously reported, Canaccord analyst Camilo Lyon upgraded Foot Locker (FL) to Buy from Hold, stating that he believes the company is approaching the end of the inventory clearance cycle it has been in for the past three quarters. His recent travels with management made it clear that the company's relationship with Nike (NKE) is "strong and symbiotic" and that recent comp declines are due to cyclical factors, not structural ones, he added. Lyon raised his price target on Foot Locker shares to $64 from $42.
UA Under Armour
$12.45

(0.00%)

11/22/17
STFL
11/22/17
NO CHANGE
Target $12
STFL
Hold
Under Armour continued executive turnover 'troubling,' says Stifel
After The Wall Street Journal reported that Peter Ruppe, SVP of Footwear, will be leaving Under Armour, Stifel analyst Jim Duffy noted that this follows a number of other senior executive departures in the past twelve months, which he sees suggesting "troubling" instability and lack of clear direction. However, the recent addition of Patrik Frisk as President and COO holds promise to introduce leadership continuity, said Duffy, who keeps a Hold rating and $12 price target on Under Armour shares.
12/15/17
STFL
12/15/17
UPGRADE
Target $17
STFL
Buy
Under Armour upgraded to Buy from Hold at Stifel
Stifel analyst Jim Duffy upgraded Under Armour to Buy from Hold, saying he expects the company's business to be in a much better position entering 2019 and for the stock to begin to anticipate improvements before it shows in reported results. Duffy, who is looking for a return to full-price apparel and footwear sales at retail and signs of margin improvement, raised his price target on Under Armour shares to $17 from $12.
12/14/17
DBAB
12/14/17
UPGRADE
Target $11
DBAB
Hold
Finish Line upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Paul Trussell upgraded Finish Line (FINL) to Hold and raised his price target for the shares to $11 from $5. The analyst sees sector headwinds alleviating in fiscal 2018 as Nike (NKE) delivers product newness and overall inventory levels scale back, leading to a less promotional environment. He believes Finish Line's efforts to improve assortment, store experience and vendor relationships will lead to a modestly better sales results. Trussell also raised his price target for Nike shares to $76 from $61 and for Under Armour (UAA) to $12 from $11.
11/15/17
BARD
11/15/17
NO CHANGE
Target $17
BARD
Outperform
Under Armour showing signs of better demand and execution, says Baird
Baird analyst Jonathan Komp said there are signs for Under Armour of better reception for the Curry 4 basketball shoe and better execution too. He believes it may still be early but the rebound in the Curry shoe, continued international strength, and broadening distribution could provide ingredients for a return to healthier footwear growth in the upcoming quarters. Komp maintained his Outperform rating and $17 price target on Under Armour shares.
UAA Under Armour
$13.82

(0.00%)

COOL PolarityTE
$24.19

-1.95 (-7.46%)

ACRS Aclaris Therapeutics
$24.72

-0.38 (-1.51%)

09/19/17
CANT
09/19/17
NO CHANGE
Target $50
CANT
Overweight
Public FDA meeting positive for Aclaris, says Cantor
The FDA last Monday conducted a public meeting on alopecia areata patient-focused drug development, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The meeting was constructive on alopecia as a disease and the need to get drugs approved, the analyst contends. She believes the meeting is a positive for Aclaris Therapeutics, which she notes is working on "several solutions to the problem." Chen has an Overweight rating on Aclaris with a $50 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $50
CANT
Overweight
Aclaris Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Aclaris Therapeutics with an Overweight rating and $50 price target.
04/26/17
LEER
04/26/17
NO CHANGE
Target $54
LEER
Outperform
Aclaris patent could be worth $15 per share, says Leerink
Leerink analyst Seamus Fernandez believes the A-101 patent announced today by Aclaris Therapeutics could add $15 per share to the company's net present value. The newly allowed patent expires in 2035, 11 years later than the analyst currently assumes loss of exclusivity in seborrheic keratosis. Extending the patent life of A-101 could increase the NPV contribution to $31 per share from $16, Fernandez tells investors in a research note. He keeps an Outperform rating on Aclaris with a $54 price target.
CSX CSX
$57.31

-0.38 (-0.66%)

12/01/17
UBSW
12/01/17
NO CHANGE
Target $68
UBSW
Buy
CSX upside remains compelling, says UBS
UBS analyst Thomas Wadewitz met with CSX management and said the new COO brings a thoughtful approach and fresh perspective on the business. The analyst believes the company is set up to deliver a significant improvement in its network operation and compelling cost reduction in 2018. He said capital expenditures will decrease and its stock buyback remains underappreciated. Wadewitz reiterated his Buy rating and $68 price target on CSX shares.
11/17/17
UBSW
11/17/17
NO CHANGE
Target $68
UBSW
Buy
CSX shares attractive, reflecting too much caution, says UBS
UBS analyst Thomas Wadewitz said CSX is in transition and is expected to be focused on improving operational execution with rising momentum in the first half of 2018 while switching to focusing on volumes and growth a longer term priority. The analyst said that given the company's potential the shares are reflecting too much caution. He reiterated his Buy rating and $68 price target on CSX shares.
11/13/17
GSCO
11/13/17
INITIATION
Target $45
GSCO
Sell
CSX initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Matt Reustle started CSX with a Sell rating and $45 price target. The analyst started the Rails sector with a Cautious coverage view and the Airfreight/Logistics sector with an Attractive coverage view. Reustle believes investors are "overestimating the speed and magnitude" of the earnings benefits from CSX's turnaround. He sees headwinds to the company's margin initiatives and notes the stock has outperformed since initial press speculation of the appointment of Hunter Harrison as CEO.
12/15/17
SBSH
12/15/17
NO CHANGE
Target $58
SBSH
Buy
CSX CEO leave to bring 'material' stock pressure, says Citi
Citi analyst Christian Wetherbee expects shares of CSX to be under "meaningful pressure" in the short term following last night's announcement that CEO Hunter Harrison will be taking a medical leave due to unexpected complications from a recent illness. The news triggers the "substantial key man risk" that has been present since Hunter took the reins in January, Wetherbee tells investors in a research note. He notes CSX's market capitalization has increased $10B since Harrison joined the company. The analyst keeps a Buy rating on the shares with a $58 price target, however. He believes Jim Foote's arrival "should cushion the blow somewhat."
RDUS Radius Health
$28.66

-0.96 (-3.24%)

05/22/17
JPMS
05/22/17
NO CHANGE
Target $74
JPMS
Overweight
Amgen data a 'clear positive' for Radius Health, says JPMorgan
JPMorgan analyst Jessica Fye believes the imbalance in observed cardiovascular serious adverse events reported by Amgen (AMGN) and UCB over the weekend for Evenity is a "clear positive" for Radius Health (RDUS). The FDA will now add results from the Phase 3 ARCH study to the regulatory review, and as a result Amgen does not expect U.S. approval for Evenity in 2017, Fye tells investors in a research note. The update is a "clear positive" for Radius Health, who has Tymlos already approved with a clean clinical safety profile, the analyst contends. She continues to believe Tymlos is well positioned for a successful launch into the large market opportunity of postmenopausal women with osteoporosis at high risk of fracture. Fye has an Overweight rating on Radius with a $74 price target. The stock in premarket trading is up 13%, or $4.62, to $39.55.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
12/06/17
SBSH
12/06/17
INITIATION
Target $30
SBSH
Neutral
Radius Health initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas started Radius Health with a Neutral rating and $30 price target. The analyst believes the Tymlos launch will be the key story for 2018 and prefers to wait on the sidelines until the company's cancer program comes to the forefront.

TODAY'S FREE FLY STORIES

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change at Goldman Sachs »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated at First Analysis »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

, ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

16:35
07/20/18
07/20
16:35
07/20/18
16:35
Hot Stocks
Lincoln Electric expands board to 11 directors, appoints Patrick Goris to board »

Lincoln Electric (LECO)…

LECO

Lincoln Electric

$92.26

0.64 (0.70%)

ROK

Rockwell Automation

$171.32

-0.71 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

KMX

CarMax

$77.15

-0.57 (-0.73%)

16:33
07/20/18
07/20
16:33
07/20/18
16:33
Hot Stocks
CarMax chairman sells 37,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$100.65

-0.74 (-0.73%)

16:31
07/20/18
07/20
16:31
07/20/18
16:31
Hot Stocks
Lowe's names Joseph McFarland as EVP of stores »

Lowe's Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
07/20/18
07/20
16:30
07/20/18
16:30
Options
Preliminary option volume of 20.2M today »

Preliminary option volume…

PFE

Pfizer

$37.33

-0.03 (-0.08%)

16:26
07/20/18
07/20
16:26
07/20/18
16:26
Hot Stocks
FDA approves Pfizer's Biosimilar NIVESTYM for all indications »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

JCP

J.C. Penney

$2.50

-0.065 (-2.53%)

16:23
07/20/18
07/20
16:23
07/20/18
16:23
Hot Stocks
J.C. Penney chief customer officer McFarland to leave company »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/20/18
07/20
16:20
07/20/18
16:20
Options
Closing CBOE SPX and VIX Index summary for July 20th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$3.15

-0.1 (-3.08%)

16:18
07/20/18
07/20
16:18
07/20/18
16:18
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/20/18
07/20
16:17
07/20/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/20/18
07/20
16:16
07/20/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

16:15
07/20/18
07/20
16:15
07/20/18
16:15
Periodicals
Disney fires 'Guardians' director after controversial tweets, THR says »

Disney has fired James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.